In silico identification and validation of inhibitors of the interaction between neuropilin receptor 1 and SARS-CoV-2 Spike protein

Samantha Perez-Miller^{1,2,†}, Marcel Patek^{3, †}, Aubin Moutal¹, Carly R. Cabel^{4, 5}, Curtis A.

5 Thorne^{4, 5, 6}, Samuel K. Campos^{5, 6, 7}, and Rajesh Khanna^{1, 2, 8 *}

¹Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, United States; ²The Center for Innovation in Brain Sciences, The University of Arizona Health Sciences, Tucson, Arizona 85724, USA; ³Bright Rock Path Consulting, LLC, Tucson, Arizona; ⁴Department of Cellular & Molecular Medicine, College of Medicine, The University of Arizona; ⁵Cancer Biology Graduate Interdisciplinary Program, University of Arizona, ⁶Bio5 Institute, University of Arizona, ⁷Department of Immunobiology, College of Medicine, University of Arizona; and ⁸Regulonix LLC, 1555 E. Entrada Segunda, Tucson, AZ 85718, USA.

[†]Contributed equally to this work

^{*}To whom correspondence should be addressed: Dr. Rajesh Khanna, Department of Pharmacology, College of Medicine, University of Arizona, 1501 North Campbell Drive, P.O. Box 245050, Tucson, AZ 85724, USA Office phone: (520) 626-4281; Fax: (520) 626-2204; Email: rkhanna@arizona.edu

Abstract

25 Neuropilin-1 (NRP-1) is a multifunctional transmembrane receptor for ligands that affect developmental axonal growth and angiogenesis. In addition to a role in cancer, NRP-1 is a reported entry point for several viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of coronavirus disease 2019 (COVID-19). The furin cleavage product of SARS-CoV-2 Spike protein takes advantage of the vascular endothelial growth factor

30 A (VEGF-A) binding site on NRP-1 which accommodates a polybasic stretch ending in a C-terminal arginine. This site has long been a focus of drug discovery efforts for cancer therapeutics. We recently showed that interruption of the VEGF-A/NRP-1 signaling pathway ameliorates neuropathic pain and hypothesize that interference of this pathway by SARS-CoV-2 spike protein interferes with pain signaling. Here, we report hits from a small molecule and

35 natural product screen of nearly 0.5 million compounds targeting the VEGF-A binding site on NRP-1. We identified nine chemical series with lead- or drug-like physico-chemical properties. Using an ELISA, we demonstrate that six compounds disrupt VEGF-A-NRP-1 binding more effectively than EG00229, a known NRP-1 inhibitor. Secondary validation in cells revealed that almost all tested compounds inhibited VEGF-A triggered VEGFR2 phosphorylation. Two

40 compounds displayed robust inhibition of a recombinant vesicular stomatitis virus protein that utilizes the SARS-CoV-2 Spike for entry and fusion. These compounds represent a first step in a renewed effort to develop small molecule inhibitors of the VEGF-A/NRP-1 signaling for the treatment of neuropathic pain and cancer with the added potential of inhibiting SARS-CoV-2 virus entry.

45 **Keywords:** Neuropilin-1, VEGF-A, SARS-CoV-2, natural compounds, ELISA, VSV, small molecules, pain, cancer,

Introduction

As of September 21, 2020 COVID-19 has infected more than 31 million people and caused nearly 1 million deaths worldwide¹. This disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which primarily gains entry to cells via binding of SARS-CoV-2 Spike glycoprotein to angiotensin converting enzyme 2 (ACE-2) and subsequent endocytosis²⁻⁴. Recent reports have identified additional entry points, including neuropilin 1 (NRP-1)^{5, 6}.

Neuropilins are cell surface receptors for secreted glycoproteins with roles in neural outgrowth, cardiovascular development, immune response, as well as tumor growth and vascularization^{7, 8}. Two neuropilin isoforms, NRP-1 and NRP-2, share ~44% sequence identity in humans and function in different pathways^{7, 8}. Both share a modular architecture with three extracellular domains, a single transmembrane helix, and a short cytoplasmic tail (**Figure 1A**)⁹. The a1a2 modules, homologous to CUB (for complement C1r/C1s, Uegf, Bmp1) domains, interact with semaphorin 3A (SEMA3A) to mediate stimulation of growth cone collapse in developing neurons⁷. The b1b2 modules are homologous to the C-terminal domains of blood coagulation Factors V and VIII⁷. The c domain, homologous to meprin, A5, and mu-phosphatase (MAM), was initially thought to be involved in dimerization, but is more likely to contribute to complex assembly by positioning the preceding domains away from the membrane¹⁰. The single transmembrane helix contributes to homo and heterodimerization¹¹ and the C-terminal cytoplasmic tail is thought to contribute to signaling through synectin, stimulating receptor-mediated endocytosis⁸.

It is through the b1 module that SARS-CoV-2 may gain entry, by taking advantage of the interaction site for vascular endothelial growth factor A (VEGF-A). VEGF-A isoforms and other growth factors that terminate in a polybasic stretch ending with an obligatory arginine residue,

termed the C-terminal end arginine (CendR) rule¹², interact with an acidic pocket formed by loops extending from the beta-barrel of b1 (**Figure 1B**)^{13, 14}. The structure of the heparin binding domain of the 164 residue isoform of VEGF-A (VEGF-A₁₆₄) confirmed that the C-terminal Arg (Arg164) engages the NRP-1 b1 domain pocket with the guanidine forming a bidentate salt-bridge with conserved Asp320 and the carboxylate forming hydrogen bonds to conserved Ser346, Thr349, and Tyr353 (**Figure 1C**)¹⁴. It is notable that VEGF-A binds to both NRP-1 and NRP-2, but has higher affinity for NRP-1 due to amino acid substitutions within the first loop region of NRP-1 that provide additional contacts between NRP-1 Thr299 and VEGF-A Glu154 (**Figure 1B, C**)¹⁴. Furthermore, although b1 and b2 are homologous domains, critical residues within the loops of the binding domain are not conserved with the result that the CendR interaction site is not present on b2.

VEGF-A has long been known for its essential role in blood vessel growth and function, but has more recently been shown to be pro-nociceptive¹⁵. VEGF-A is a selective endothelial cell mitogen that promotes angiogenesis, primarily via interaction with the VEGF receptor VEGFR2, also known as kinase insert domain-containing receptor (KDR)¹⁶. Alternative splicing of the VEGF-A gene produces several isoforms of the mature protein containing between 121 and 206 amino acid residues, with VEGF-A₁₆₅ being pro-nociceptive¹⁷ via sensitization of transient receptor potential (TRP) channels¹⁸ and ATP-gated purinergic P2X_{2/3} receptors¹⁹ on dorsal root ganglion (DRG) neurons. This alternative splicing is dependent on serine-arginine rich protein kinase 1 (SRPK1) which mediates the phosphorylation of serine-arginine rich splice factor (SRSF1)^{17, 20, 21}. VEGF binding to VEGFR2, a co-receptor for NRP-1, is associated with receptor dimerization and activation that triggers downstream signaling pathways including phosphatidylinositol 3-kinase (PI3-K)/Akt and phospholipase C gamma/extracellular signal-

regulated kinase (PLCg/ERK)¹⁶. Clinical findings that VEGF-A contributes to pain are supported by observations that in osteoarthritis increased VEGF expression in synovial fluids has been associated with higher pain scores²². VEGF-A has been reported to enhance pain behaviors in normal, nerve-injured and diabetic animals^{17, 23}.

It is known that neuropilins are entry points for several viruses, including human T-lymphotropic virus-1 (HTLV-1)²⁴ and Epstein-Barr virus (EBV)²⁵. In both cases, furin processing of viral glycoproteins results in polybasic CendR motifs that directly interact with the VEGF-A site on the NRP-1 b1 domain²⁶. Compared to SARS-CoV-1, the causative agent of SARS, mutation in the furin cleavage site of SARS-CoV-2 results in production of a CendR motif (⁶⁸²RRAR⁶⁸⁵) which was shown to bind to the neuropilin b1 VEGF-A site, suggesting NRP-1 as a possible route of viral entry^{5,6}. The importance of NRP-1 is supported by recent evidence of upregulated NRP-1 in lung samples from COVID-19 patients⁵.

These connections raise an interesting question: does interference with the VEGF-A/NRP-1 signaling pathway by SARS-CoV-2 result in dampened pain? This question has been examined by our laboratory; we recently showed that SARS-CoV-2 Spike protein binding to NRP-1 prevents VEGF-A signaling and reduces neuropathic pain in an animal model²⁷. Thus, NRP-1 represents a novel target for treating neuropathic pain²⁷. Furthermore, targeting NRP-1 also presents a unique approach to inhibiting viral entry and/or re-entry into cells to reduce viral load. Due to its role in cancer, NRP-1 has been a target for drug design for over 20 years. During this time, discovery efforts have focused on development of NRP-1 antibody therapies^{9, 28-33}, including a recent dual-specificity antibody to VEGFA and NRP-1^{32, 33}, peptides that target transmembrane domain interactions^{11, 34-37} or the CendR interaction site^{12, 31, 38-53}, as well as small-molecules that target the CendR site⁵⁴⁻⁶¹. With one exception⁴³, the CendR site targeting

peptides contain a CendR motif, even those which are cyclical^{39, 45, 46, 49} or branched^{51, 53}. Two of the most well-known small molecule NRP-1 inhibitors, EG00229 and EG01377, contain a terminal Arg-like moiety and carboxyl group known to be key to interaction with NRP-1^{54, 61} as does the newly developed fluorescent compound based on EG01377⁶². The remaining known small molecule compounds consist of an arginine-derivative series⁶⁰ and several diverse chemotypes such as acylthioureas⁵⁶, benzamidulosulfonamides⁵⁹, bis-guanidines⁵⁵, or aryl benzylethers⁵⁸. Many of these small molecule compounds contain functional groups of suboptimal physico-chemical and ADME properties.

In order to identify unique compounds that could be used to interrogate the role of these signaling complexes in pain, we conducted a virtual screen of nearly 0.5 million compounds against the NRP-1 CendR site, resulting in nearly 1,000 hits. Here, we present 9 chemical series of synthetic and natural compounds with lead- or drug-like physico-chemical properties and identify a pharmacophore model which will guide future design of compounds. We also show that six of the compounds interfere with VEGF-A binding more effectively than EG00229, a known NRP-1 inhibitor and three interfere with VEGF-A binding as well as the furin-cleaved Spike S1 domain. Furthermore, our compounds show inhibition of VEGF-A triggered VEGFR2 phosphorylation in a cell-based assay. Finally, two of the compounds inhibited antiviral activity.

Results and Discussion

We conducted virtual screens against the VEGF-A binding site on the NRP-1 b1 domain using three libraries: a ~211 K synthetic compound library (DIV) from ChemBridge; a ~257 K natural compound library (NC1) obtained from the COLleCtion of Open NatUral productS (COCONUT) resource⁶³; and a ~20 K (NC2) natural compound library from the ZINC15

database⁶⁴. The screens were run once without ligand-receptor interaction constraints and

repeated with the constraint that compounds form a hydrogen bond to Asp 320, a key residue for coordinating the terminal arginine in the CendR motif¹⁴. This constraint was used in attempt to select for compounds that interact in a similar way as observed for VEGF-A¹⁴, known inhibitors^{42, 54, 60, 61} and modeled SARS-CoV-219 CendR terminal arginine⁶. However, application of this constraint led to reduced overall scores and strained conformations for most compounds in the DIV and NC1 libraries. Therefore, we report only the unconstrained screen results for these libraries and both constrained and unconstrained results for the NC2 screen.

Selection of top compounds

The combined output of the four screens produced a total of 1,147 hits. Compounds from each screen were sorted by Glide XP GScore (kcal/mol) and visually inspected for substructure match of core scaffolds and patterns of chemically reactive moieties while considering the diversity of chemotypes. Compound representatives with scaffold decoration that suggested initial structure activity relationships (SAR) were extracted and grouped into series resulting in a set of nine diverse chemotypes (series). These series include both small synthetic molecules and natural products (**Table 1**). While calculated property ranges vary for the chemotype and drug indication, we intend to keep compounds in our series such that molecular weight (Mw) < 400 Da, calculated octanol-water partition coefficient (clogP) < 3.5, and calculated solubility (clogS) at pH 7.4 > -5 M. Consequently, we expect the initial absorption, distribution, metabolism, and excretion (ADME) profile of the series to be acceptable (e.g., good hepatocyte clearance and bioavailability). To assess the probability that hit series compounds are orally available, we determined components and overall compliance with Lipinski rule of 5 (Ro5)^{65, 66}. Since the Ro5

guidelines were derived for orally available small molecules, we did not use this binary parameter for the classification of natural products. Also, since solubility and CNS penetration rules originated from small molecule sets, these calculations are not applicable to natural products and were also omitted. Furthermore, detailed inspection of data of **Table 1** revealed that natural product compounds **11**, **12**, and **15** are in fact small molecule chemotypes. Correspondingly, all molecular descriptors were calculated for these compounds and they were considered part of the small molecule set.

Since one objective of inhibiting the VEGF-A/NRP-1 interaction is disruption of pain signals, the full therapeutic effect will require drug exposure in the central nervous system (CNS). Correspondingly, the optimization strategy for these compounds will include modifications beneficial for crossing the blood-brain barrier (BBB), for example, decreasing the number of hydrogen bond donors and polarity. To supplement traditional medicinal chemistry approaches to increasing CNS exposure, we implemented the BBB score algorithm of Weaver et al.⁶⁷ as one of the optimization parameters. Values of the BBB score in the range of 4 to 6 correctly predict 90% of CNS drugs⁶⁷. While the brain/plasma ratio will be experimentally assessed for series representatives, optimization will be additionally guided by surrogate estimates of passive diffusion (PAMPA) and assessment of efflux and transporter proteins using assays in MDCK cell lines. Overall, predicted physico-chemical properties of all small molecule hit series (series 1-6) fall within ranges of lead-like and/or drug-like molecules (**Table 1**). Moreover, several representatives of series 1 and 2 are expected to have acceptable CNS exposure.

Series analysis and docked binding modes

After initial ranking and selection of the top 20 hits, we proceeded to a more detailed analysis of structural and chemical features of the compounds. Chemical structures of all twenty hits and one virtual SAR analog are shown in **Figure 2**. Hits are grouped by common core motifs and molecular fragments that engage in productive hydrogen bond (HB) and alkyl/aryl π -contacts within the binding pocket. Inspection of aligned 2-D structures makes it apparent that the 2(1H)-pyridone core of structure **15** (highlighted in **Figure 2**) is the minimal motif of all small molecule hits (discussed further below). This core binds near the top of a central hydrophobic box formed by residues Tyr297, Tyr253, Trp301, and the methyl group of Thr316 (**Figure 3**). As expected, all of the hits bind within this box with the aryl or alkyl (e.g. isobutyl) groups engaged in hydrophobic interactions with these residues. Indeed, it is these hydrophobic interactions that are drivers of the overall binding affinity as judged by the Glide XP Gscore.

From this central position, the hits extend out of the aryl box in two general binding modes, which we refer to as Mode I (**Figure 4A**) and Mode II (**Figure 4B**). Interestingly, it is the core lactam carbonyl group in compounds **1-12**, **15**, **19-20** that makes potential hydrogen bonds with the hydroxyl groups of Thr349 and Tyr353 (**Figure 4C, D**) whereas in **14**, **16-18** the carbonyl in the carboxylic group make these contacts, and in **13**, **19**, **20** the carboxyl makes contacts with S346, T349, and Y353 (**Figure 4E**). Thus, all of compounds are able to partially mimic the terminal carboxyl contacts that are considered to be critical for anchoring the terminal Arg of CendR peptides^{12, 31, 38-42, 44-53} (**Figure 1C**) or known small molecule mimetics and inhibitors that contain a terminal guanidyl from Arg moiety and carboxylic group^{54, 61, 62}.

All of the hit molecules occupying Mode I are synthetic compound chemotypes, including **11**, **12**, and **15** from the NC1 and NC2 libraries, as noted above. Functional groups in **1**, **2**, **4**, **5**, **10**, **12**, **13** are involved in one or more potential hydrogen bond contacts with polar

side chains Ser298 and Asn300 (**Figure 4C, D**). No other heteroatoms nor N-H hydrogen in pyrimidone (**1, 4, 5, 10, 11**), 2-pyrimidone (**2, 3, 6**), or 4H-1,2,4-triazin-5-one (**7, 8**) scaffolds are seemingly engaged in productive binding. Such "silent" polar sites provide the opportunity for replacement and optimization of ADME properties (e.g., oral absorption, systemic/CNS distribution) of these compounds. Interestingly, upon detailed analysis of hydrogen-bond patterns, we noticed that series **1, 3** but also **2-6** feature H-donor/H-acceptor topology of kinase inhibitors, including the presence of hydrophobic residues found in hinge-binding ATP mimics. Such features warrant the inclusion of kinase selectivity panels in the optimization stage. While kinase activity might be a feature to optimize out, our validation experiments support that binding of compounds from our series to the CendR site on NRP-1 (discussed below).

Mode II, with the exception of compound **9**, features skeletons of natural compounds. The functional groups in molecules **14** and **16-20** possess extensions toward the base of the pocket that form ionic or hydrogen bond contacts to residue Asp320 (**Figure 4E**). Furthermore, compound **9** extends toward the open region of the binding pocket bordered by Gly318 and Glu319 (**Figure 4F**). In preliminary SAR for compound **9**, we found that augmenting these interactions by the replacement of 5-methylisoxazole with 5-aminopyrazole (**9a, Figure 2**) led to an improvement in the Glide XP Gscore of 1.4 kcal/mol. Exploration of the interaction patterns observed in both binding modes is expected to improve binding affinity and compound selectivity.

We note that molecules **13** and **16**, while having the key pharmacophores present, had their geometry altered during the ligand preparation, likely a result of missing or incorrect chiral information in the COCONUT library, a known potential issue⁶³. The hydroxycinnamyl group in **13** is present in the less stable Z-conformation and the chiral center at phenylalanine in **16** has

inverted to (R)-configuration. Such alterations made both analogs unavailable from commercial sources of natural products. However, due to the availability of both precursors, derivatives **13** and **16** can be synthesized. Finally, the last two compounds (**19, 20**) are ionic, moderately reactive compounds which are not considered to be drug-like. Nevertheless, since both match the key features of CendR peptides (N-acylarginine), they provide valuable points for SAR.

Comparison to known small molecules

To enable comparison with small molecules reported by others we docked and calculated physico-chemical properties of seven compounds that also target the NRP-1 CendR site^{54-56, 58-61}.

Based on chemotypes, we assigned these six molecules into unique series **10-14** (**Figure 5**). These molecules all exhibited lower docking scores than our hits (**Table 1**). Moreover, several of compounds **A-F** feature functional groups known for contributing to suboptimal physico-chemical and ADME properties, such as solubility, low intestinal absorption, metal chelation, and lability in liver microsomes or hepatocytes (**Table 1**). Docking poses for all compounds except **E** adopted Mode II binding.

Validation of selected hits

We evaluated the ability of hit compounds to interfere with the NRP-1/VEGF-A interaction using an enzyme linked immunosorbent assay (ELISA). We coated plates with the extracellular domain of human NRP-1 (containing the a1a2 and the b1b2 regions) and added a selection of our compounds (based on SAR and commercial availability) to disrupt the NRP-1/VEGF-A interaction. We found that 3 hit compounds blocked more than 50% of VEGF-A binding to NRP-1. This level of inhibition mimicked that we observed with SARS-CoV-2 Spike

protein (**Table 1**). In comparison, EG00229's level of inhibition was outmatched by 6 of the 9
 255 compounds we screened in this assay (**Table 1**). Thus, three of the synthetic compounds
 significantly inhibited the interaction between VEGF-A and NRP-1, confirming that they
 compete for binding to the CendR site (**Table 1**).

Compounds for biochemical evaluation were selected such that each structural feature
 was complementary to the overall SAR. Relative inhibition in the ELISA is reported in **Table 1**.
 260 Unfortunately, several compounds (**12, 14, 15, 18, 19, 20**) were not commercially available.
 Since many of those compounds can be synthesized in two to five steps, we intend to make
 essential representatives during future SAR optimization.

Inspection of docking scores and relative inhibition data in **Table 1** reveals a correlation
 between predictions and ELISA data. Most importantly, the binding hypotheses were confirmed
 265 as compounds with pyridone and pyrimidone cores, when appropriately decorated, were found to
 disrupt the VEGF-A/NRP-1 interaction more effectively than EG00229 and to a similar extent as
 SARS-CoV-2 Spike protein. As could be expected, interference was greater for compounds with
 additional functional groups (**1, 2, 4, 5** vs. **7, 8, 11**). Such a trend is important for the design of
 new analogs that will expand on underexplored scaffolds (**Series 3**, compound **11**). As discussed
 270 later, we intend to improve binding and inhibition by borrowing structural features from Modes I
 and II (e.g., compound **9a**).

Next, we set out to test the compounds for their capacity to inhibit the activation of the
 VEGF-A pathway. VEGF-A binding to the dimeric complex of its receptor VEGFR2 and co-
 receptor NRP-1 triggers phosphorylation of the VEGFR2 cytoplasmic domain at Y1175 (**Figure**
 275 **6A**). Using an in-cell Western assay, we tested the compounds for their ability to inhibit
 increased phosphorylation of VEGFR2 by VEGF-A. In this assay, VEGF-A doubled the level of

VEGFR2 phosphorylation at Y1175 (**Figure 6B**) which could be blocked by SARS-CoV-2 Spike protein as well as by the reference compound EG00229 (**Figure 6C**). All 9 of our tested compounds significantly blocked the VEGF-A stimulated increased phosphorylation of VEGFR2 (**Figure 6**). In the absence of stimulation by VEGF-A, only one of the 9 compounds (**4**) showed inhibition of basal VEGFR2 phosphorylation. As mentioned above, several of our compounds do exhibit features that are consistent with known kinase inhibitors which will be addressed during optimization of these hits.

Finally, we screened the compounds for antiviral activity using a GFP-expressing vesicular stomatitis virus (VSV) recombinant protein, encoding the SARS-CoV-2 spike protein rather than the native envelope glycoprotein⁶⁸. This VSV-eGFP-SARS-CoV-2 mimics SARS-CoV-2 and is a convenient BSL2 platform to assess SARS-CoV-2 Spike-dependency. Vero-E6-TMPRSS2 cells, which overexpress the transmembrane serine protease 2 (TMPRSS2)⁶⁸, were infected in the presence of individual compounds or DMSO vehicle. GFP fluorescence was measured 36 hours post infection by automated microscopy (**Figure 7A**). Two compounds (**1** and **5**) displayed >50% inhibition of VSV-eGFP-SARS-CoV-2 antiviral activity while another two compounds (**16a**, **17**) demonstrated ~15% inhibition (**Figure 7B**). Spike inhibited antiviral activity by ~35% while the known NRP-1 inhibitor EG00229 was ineffective in this assay.

Pharmacophore models

A pharmacophore model was derived from the identified ligands, considering both steric and electronic requirements (**Figure 8**). The most critical features are the aromatic rings A1, A2, and the hydrogen bond acceptor HBA. This HBA is typically a carbonyl oxygen engaged in contacts with the hydroxyl groups of Tyr353 and Thr349. The aryl group in A1 directs the

carbonyl oxygen of the HBA toward those residues. Alternatively, A1 can be presented in an edge-to-face contact with Tyr297. There are two additional acceptor sites on the opposite side of the A1 ring, relative to acceptor HBA. These can form hydrogen bonds with the side chain of the Asn300 amide or the Ser298 hydroxyl. The area between the HBA and these two additional acceptors (where the label A1 is located) is expected to accommodate a structural molecule of water^{9, 13, 60, 61}. This water has been proposed to be important in ligand binding as it may bridge interactions to Trp301⁶⁰. However, our screens were conducted in the absence of water molecules. Nevertheless, we observe that polar groups in several analogs occupy the position of this structural water and get involved in the corresponding hydrogen bond network, suggesting they could displace it. Aromatic ring A2 is sandwiched in the hydrophobic box formed by residues Y353, W301, Y297, and the methyl group of T316. Binding mode II includes A1/HBA, A2, and features an expansion toward polar residues (E319, D320) and additional stabilizing contacts in the lower part of the pocket. It is this area (donor, donor, acceptor) which accepts the guanidino group of the CendR Arg and contains the open lower left pocket seen in Mode I (Figure 4A). By connecting all important pharmacophore features, hybrid synthetic molecules can be envisioned that will merge binding modes I and II and extend into the lower left to fully occupy the available binding pocket.

Conclusions

From a virtual screen of nearly 0.5 M compounds, we identified nine chemical series comprising small molecules and natural products that occupy the CendR binding site on NRP-1. All compounds identified in our series fall within ranges of lead-like and/or drug-like molecules which enhances their potential for efficacy in *in vitro* and *in vivo* assays. This *in silico* effort

allowed us to identify two modes of binding within the CendR pocket. To guide future drug discovery efforts, we propose a hybrid pharmacophore model that will enable design of small molecules that will maximize the pocket occupancy. Two validation experiments confirmed that a subset of our hits compete with binding of VEGF-A and interfere with VEGF-A induced phosphorylation of VEGFR2, supporting direct binding to the CendR site on the b1 domain. Two CendR-blocking compounds inhibited Spike-dependent infection of VSV-eGFP-SARS-CoV-2 and may have potential for further development, although additional studies are needed to understand their antiviral mechanisms and involvement of NRP-1 and ACE-2 receptors. To guide future drug discovery efforts, we propose a hybrid pharmacophore model that will enable design of small molecules that will maximize pocket occupancy and contacts. Since the VEGF-A/NRP-1 signaling pathway participates in multiple pathologies including neuropathic pain and cancer, our series of lead compounds represent a first step in a renewed effort to develop small molecule inhibitors for the treatment of these diseases.

Finally, we mention one additional interesting aspect of this system that is still being explored. Heparin, the widely used anticoagulant drug is routinely used for hospitalized SARS-CoV-2 patients to lower the probability of blood clotting and embolism⁶⁹. It is also known that heparin prevents infection by a range of viruses⁷⁰ and was recently reported to inhibit invasion by SARS-CoV-2 in a cell-based assay⁷¹. Heparin is a required co-receptor for VEGF-A signaling⁷² and NRP-1 also binds heparin, mainly through the b1b2 domain, through sites distal to the CendR pocket⁷³. This raises the possibility that the interaction of SARS-CoV-2 Spike/RBD with NRP-1 is facilitated by heparin and invites speculation of a potential synergistic effect of heparin and NRP-1 inhibitors as an efficacious drug combination to prevent viral entry.

Methods

Preparation of receptor protein and grid for virtual screening

Preparation and virtual screening steps were conducted using Schrödinger Release 2019-3

350 (Schrödinger, LLC, New York, NY, 2020). The highest resolution structure of the NRP-1 b1 domain was selected for docking (PDB ID: 6fmc)⁶¹. This structure was prepared using the Protein Preparation Wizard⁷⁴ to remove all water molecules and alternate conformations, add and refine hydrogen atoms, and conduct restrained minimization (OPLS3e force field, convergence to 0.30 Å). There were no residues with alternate conformations within the binding pocket. A
355 20x20x20 Å grid box was centered on the co-crystallized inhibitor EG01377 to target the VEGF-A₁₆₅ site. An optional, symmetric constraint was generated that required hit compounds to form a hydrogen bond to the side-chain of Asp 320.

Screening libraries

360 The synthetic compound library (DIV) was obtained by combining ChemBridge Diversity Core and Express sets of drug-like compounds. These were prepared for screening in LigPrep using the OPLS3e force field, neutral ionization, desalting, and tautomer generation. If specified, chirality centers were maintained, otherwise up to three chiral variations were generated per atom and ligand. This library contained a total of 210,677 compounds (293,251 conformers). The
365 COLleCtion of Open NatUral producTs (COCONUT) set of open-access natural compounds⁶³ was downloaded from <https://zenodo.org/record/3778405#.Xs1D6mhKiUk> (on 5/26/20) and prefiltered by excluding compounds with molecular weight ≥ 500 Da and alogP ≥ 5 . LigPrep settings were the same as for the DIV set and the resulting library (NC1) consisted of 257,166

natural compounds (50,686 conformers). The smaller natural compound library (NC2) library

was a curated set of 20,088 natural compounds (23,846 conformers) originally obtained from ZINC15⁶⁴. The NC2 library had some overlap with the NC1 library, but nevertheless produced useful results.

Virtual screening and scoring

Virtual screens were run for each library against the VEGF-A₁₆₅ binding site of NRP-1 using the Glide virtual screening workflow (Schrödinger, LLC, New York, NY, 2020)⁷⁵. For the DIV and NC1 libraries, the default docking settings were accepted, with 10% of compounds at each stage (high-throughput virtual screen, standard precision docking, extra precision docking) resulting in 293 hits for the DIV library and 550 hits for the NC1 library. Because the NC2 library was smaller, it was set to retain 25%, 20%, 15% of the hits at each stage, resulting in 152 hits. The virtual screens were first run without and then with the use of the Asp 320 constraint, but only the constrained hits from NC2 were retained due to strained conformations and lower docking scores for the DIV and NC1 screens. Thus, a total number of 1,147 virtual hit compounds were obtained from 4 screens.

Docking of known NRP-1 targeting compounds

Representatives of known compound series^{54-56, 58, 59, 61} were prepared for screening in LigPrep using the OPLS3e force field, neutral ionization, desalting, and tautomer generation. Docking was run against the VEGF-A₁₆₅ binding site of NRP-1 using Glide XP (Schrödinger, LLC, New York, NY, 2020)⁷⁵.

Compound property calculations

The following physico-chemical properties were calculated using RDKit⁷⁶: molecular weight in Daltons (Mw, Da), partition coefficient (clogP), number of hydrogen-bond donors and acceptors (HB-D, HB-A), total number of N-H and OH groups (NHOH), number of rotatable bonds (RotB), and total polar surface area (TPSA, Å²). To estimate compound solubility, calculated logS (M) at pH=7.4 was obtained using ChemAxon Aqueous solubility module⁷⁷.

ELISA-based NRPI-VEGF-A165 protein binding assay

Plates (96-well, Nunc Maxisorp; Thermo Fisher Scientific, Waltham, MA, USA) were coated with human Neuropilin-1-Fc (10 ng per well, Cat# 50-101-8343, Fisher, Hampton, NH) and incubated at room temperature overnight. The following day, the plates were washed and blocked with 3% BSA in PBS to minimize non-specific adsorptive binding to the plates. SARS-CoV2 Spike protein (100 nM, S1 domain aa16-685, Cat# Z03485, Genscript, Piscataway, NJ), EG00229 (Cat#6986, Tocris) or the indicated compounds were added at 12.5μM and incubated for 30 min at room temperature prior to adding biotinylated human VEGF-A165 (Cat#BT293, R&D systems) at 10 nM. As a negative control, some wells received PBS containing 3% BSA. The plates were incubated at room temperature with shaking for 1 h. Next, the plates were washed with PBS to eliminate unbound protein. Bound biotinylated VEGF was detected by streptavidin-HRP (Cat#016-030-084, Jackson immunoResearch). Tetramethylbenzidine (Cat#DY999, R&D Systems, St. Louis, MO) was used as the colorimetric substrate. The optical density of each well was determined immediately, using a microplate reader (Multiskan Ascent; Thermo Fisher Scientific) set to 450 nm with a correction wavelength of 570 nm. Data were normalized to the background and to the signal detected for VEGF-A165 alone.

415

In cell western for detecting inhibition of VEGFR2 activation by VEGF-A165

Mouse neuron derived Cathelamine A differentiated CAD (ECACC, Cat# 08100805) were grown in standard cell culture conditions, 37 °C in 5% CO₂. All media was supplemented with 10% fetal bovine serum (Hyclone) and 1% penicillin/streptomycin sulfate from 10,000 µg/ml stock. CAD cells were maintained in DMEM/F12 media. Cells were plated in a 96 well plate and left overnight. The next day, indicated compounds (at 12.5µM), or SARS-CoV-2 Spike (100 nM, S1 domain) were added in CAD cell complete media supplemented with 1 nM of mouse VEGF-A165 (Cat# RP8672, Invitrogen) and left at 37°C for 1 hour. Media was removed and the cells rinsed three times with PBS before fixation using ice cold methanol (5 min). Methanol was removed and cells were left to dry completely at room temperature. Anti-VEGFR2 pY1175 was used to detect the activation of the pathway triggered by VEGF-A165 in the cells. The antibody was added in PBS containing 3% BSA and left overnight at room temperature. The cells were washed three times with PBS and then incubated with Alexa Fluor® 790 AffiniPure Goat Anti-Rabbit IgG (Cat# 111-655-144, Jackson immunoResearch) in PBS, 3% BSA for 1 hour at room temperature. Cells were washed three times with PBS and stained with DAPI. Plates were imaged on an Azure Sapphire apparatus. Wells that did not receive the primary antibody were used a negative control. The signal was normalized to the cell load in each well (using DAPI) and to control wells not treated with VEGF-A165.

435 *Cell and viral culture*

Vero-E6-TMPRSS2 cells were cultured in high glucose DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were supplemented with 20 µg/mL blasticidin (Invivogen,

ant-bl-1) to maintain stable expression of TMPRSS2 during routine culture. Cells were maintained at 37°C with 5% CO₂ and passaged every 2-3 days. These African green monkey

440 Early kidney cells express NRP-1 which is 99.3% similar within its b1 domain to the human NRP-1. Homology models (not shown) also reveal no differences in NRP-1 passage between these species. infectious VSV-eGFP-SARS-CoV-2 stock was a generous gift from Sean P.J. Whelan (Washington University, St. Louis, MO, USA). VSV-eGFP-SARS-CoV-2 was passaged once by infecting Vero-E6-TMPRSS2 cells at MOI = 0.01 in DMEM + 2% FBS and 1%
445 penicillin/streptomycin for 72 hr at 34°C. Cell-free supernatant was collected and concentrated 10-fold through Amicon-Ultra 100 kDa MWCO spin filter units (Millipore UFC905008) prior to aliquoting and storage at -80°C. Titer was determined to be approximately 1x10⁷ PFU/mL as determined by median tissue culture infectious dose (TCID₅₀) assay on Vero-E6-TMPRSS2 cells.

450 *Screening compounds for VSV-eGFP-SARS-CoV-2 inhibition*

African green monkey kidney (Vero)-E6-TMPRSS2 cells were plated at 15,000 cells per well in black/clear bottom 96 well tissue culture plates (Thermo Fisher Scientific 165305). The next day cells were infected ± 0.001% DMSO, 25 µM compounds, or 68 nM recombinant Spike protein,
455 at an MOI of 0.05 in 100 µL DMEM + 10% FBS and 1% penicillin/streptomycin for 36 hr at 37°C prior to live cell fluorescent microscopy on a Nikon Eclipse Ti2 automated microscopy system with 4x objective and 488/532 nm filters. Sum GFP fluorescence intensity, normalized to cell count by HCS CellMask Blue (Thermo #H32720), was measured and for each well and plotted with Prism 6 (GraphPad Software). Significant differences were determined by RM one-

way ANOVA followed by multiple comparisons test. An alpha of 0.05 was used to determine the statistical significance of the null-hypothesis.

Acknowledgments: We thank Sean P.J. Whelan and Paul W. Rothlauf for generously sharing

the VSV-eGFP-SARS-CoV-2 clone and the Vero-E6-TMPRSS2 cells. **Funding:** Supported by NINDS (NS098772 (R.K.)), NIDA (DA042852, R.K.), NIGMS (GM136853, S.K.C.), and a UA

COVID-19 seed grant (002196, S.K.C.) **Author contributions:** R.K. and A.M. developed the concept; S.P.-M. and M.P. conducted virtual screening, docking and analysis; A.M. performed

the ELISA and in-cell western experiments and analyzed the data; S.K.C. performed the VSV-

SARS-CoV-2 infections; C.R.C. performed microscopy and collected the VSV-SARS-CoV-2

infection data; C.A.T. and S.K.C. supervised and analyzed the infection experiments. All authors wrote and edited the manuscript; and R.K. supervised all aspects of this project. All authors had

the opportunity to discuss results and comment on the manuscript; **Competing interests:** R.

Khanna is the co-founder of Regulonix LLC, a company developing non-opioids drugs for

chronic pain. In addition, R. Khanna has patents US10287334 and US10441586 issued to

Regulonix LLC. The other authors declare no competing financial interests. **Data and materials**

availability: All data is available in the main text, figures, and supplementary materials.

Abbreviations

ACE-2, angiotensin converting enzyme-2; ADME, absorption, distribution, metabolism, and

excretion; BBB, blood brain barrier; CNS, central nervous system; COCONUT, ColleCtion of

Open NatUral producTs; COVID-19, coronavirus disease 2019; ELISA, enzyme linked

immunosorbent assay; NC, natural compound; NRP-1, Neuropilin 1; PDB, protein data bank;
Ro5, Lipinski rule of 5; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VEGF-
485 A, vascular endothelial growth factor-A; VSV, vesicular stomatitis virus.

References

1. Dong, E.; Du, H.; Gardner, L., An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* **2020**, *20* (5), 533-534.
- 490 2. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Kruger, N.; Herrler, T.; Erichsen, S.; Schiergens, T. S.; Herrler, G.; Wu, N. H.; Nitsche, A.; Muller, M. A.; Drosten, C.; Pohlmann, S., SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **2020**, *181* (2), 271-280 e8.
3. Wang, Q.; Zhang, Y.; Wu, L.; Niu, S.; Song, C.; Zhang, Z.; Lu, G.; Qiao, C.; Hu,
495 Y.; Yuen, K. Y.; Wang, Q.; Zhou, H.; Yan, J.; Qi, J., Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. *Cell* **2020**, *181* (4), 894-904 e9.
4. Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q., Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. *Science* **2020**, *367* (6485), 1444-1448.
5. Cantuti-Castelvetri, L.; Ojha, R.; Pedro, L. D.; Djannatian, M.; Franz, J.; Kuivanen,
500 S.; Kallio, K.; Kaya, T.; Anastasina, M.; Smura, T.; Levanov, L.; Szirovicza, L.; Tobi, A.; Kallio-Kokko, H.; Österlund, P.; Joensuu, M.; Meunier, F. A.; Butcher, S.; Winkler, M. S.; Mollenhauer, B.; Helenius, A.; Gokce, O.; Teesalu, T.; Hepojoki, J.; Vapalahti, O.; Stadelmann, C.; Balistreri, G.; Simons, M., Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system. *bioRxiv* **2020**, 2020.06.07.137802.

- 505 6. Daly, J. L.; Simonetti, B.; Antón-Plágaro, C.; Kavanagh Williamson, M.; Shoemark, D. K.; Simón-Gracia, L.; Klein, K.; Bauer, M.; Hollandi, R.; Greber, U. F.; Horvath, P.; Sessions, R. B.; Helenius, A.; Hiscox, J. A.; Teesalu, T.; Matthews, D. A.; Davidson, A. D.; Cullen, P. J.; Yamauchi, Y., Neuropilin-1 is a host factor for SARS-CoV-2 infection. *bioRxiv* **2020**, 2020.06.05.134114.
- 510 7. Pellet-Many, C.; Frankel, P.; Jia, H.; Zachary, I., Neuropilins: structure, function and role in disease. *Biochem J* **2008**, *411* (2), 211-26.
8. Plein, A.; Fantin, A.; Ruhrberg, C., Neuropilin regulation of angiogenesis, arteriogenesis, and vascular permeability. *Microcirculation* **2014**, *21* (4), 315-23.
9. Appleton, B. A.; Wu, P.; Maloney, J.; Yin, J.; Liang, W. C.; Stawicki, S.; Mortara, K.; Bowman, K. K.; Elliott, J. M.; Desmarais, W.; Bazan, J. F.; Bagri, A.; Tessier-Lavigne, M.; Koch, A. W.; Wu, Y.; Watts, R. J.; Wiesmann, C., Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. *The EMBO journal* **2007**, *26* (23), 4902-12.
- 515 10. Yelland, T.; Djordjevic, S., Crystal Structure of the Neuropilin-1 MAM Domain: Completing the Neuropilin-1 Ectodomain Picture. *Structure* **2016**, *24* (11), 2008-2015.
- 520 11. Jacob, L.; Sawma, P.; Garnier, N.; Meyer, L. A.; Fritz, J.; Hussenet, T.; Spenle, C.; Goetz, J.; Vermot, J.; Fernandez, A.; Baumlin, N.; Aci-Seche, S.; Orend, G.; Roussel, G.; Cremel, G.; Genest, M.; Hubert, P.; Bagnard, D., Inhibition of PlexA1-mediated brain tumor growth and tumor-associated angiogenesis using a transmembrane domain targeting peptide. *Oncotarget* **2016**, *7* (36), 57851-57865.
- 525

12. Teesalu, T.; Sugahara, K. N.; Kotamraju, V. R.; Ruoslahti, E., C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. *Proceedings of the National Academy of Sciences of the United States of America* **2009**, *106* (38), 16157-62.

13. Lee, C. C.; Kreusch, A.; McMullan, D.; Ng, K.; Spraggon, G., Crystal structure of the human neuropilin-1 b1 domain. *Structure* **2003**, *11* (1), 99-108.

14. Parker, M. W.; Xu, P.; Li, X.; Vander Kooi, C. W., Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. *The Journal of biological chemistry* **2012**, *287* (14), 11082-9.

15. Llorian-Salvador, M.; Gonzalez-Rodriguez, S., Painful Understanding of VEGF. *Frontiers in pharmacology* **2018**, *9*, 1267.

16. Djordjevic, S.; Driscoll, P. C., Targeting VEGF signalling via the neuropilin co-receptor. *Drug discovery today* **2013**, *18* (9-10), 447-55.

17. Hulse, R. P., Role of VEGF-A in chronic pain. *Oncotarget* **2017**, *8* (7), 10775-10776.

18. Hulse, R. P.; Beazley-Long, N.; Hua, J.; Kennedy, H.; Prager, J.; Bevan, H.; Qiu, Y.;

Fernandes, E. S.; Gammons, M. V.; Ballmer-Hofer, K.; Gittenberger de Groot, A. C.; Churchill, A. J.; Harper, S. J.; Brain, S. D.; Bates, D. O.; Donaldson, L. F., Regulation of alternative VEGF-A mRNA splicing is a therapeutic target for analgesia. *Neurobiology of disease* **2014**, *71*, 245-59.

19. Joseph, E. K.; Green, P. G.; Bogen, O.; Alvarez, P.; Levine, J. D., Vascular endothelial cells mediate mechanical stimulation-induced enhancement of endothelin hyperalgesia via activation of P2X2/3 receptors on nociceptors. *The Journal of neuroscience : the official journal of the Society for Neuroscience* **2013**, *33* (7), 2849-59.

20. Hulse, R. P.; Drake, R. A.; Bates, D. O.; Donaldson, L. F., The control of alternative splicing by SRSF1 in myelinated afferents contributes to the development of neuropathic pain.

550 *Neurobiology of disease* **2016**, *96*, 186-200.

21. Oltean, S.; Gammons, M.; Hulse, R.; Hamdollah-Zadeh, M.; Mavrou, A.; Donaldson, L.; Salmon, A. H.; Harper, S. J.; Lodomery, M. R.; Bates, D. O., SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. *Biochemical Society transactions* **2012**, *40* (4), 831-5.

555 22. Takano, S.; Uchida, K.; Inoue, G.; Matsumoto, T.; Aikawa, J.; Iwase, D.; Mukai, M.; Miyagi, M.; Takaso, M., Vascular endothelial growth factor expression and their action in the synovial membranes of patients with painful knee osteoarthritis. *BMC Musculoskelet Disord* **2018**, *19* (1), 204.

23. Verheyen, A.; Peeraer, E.; Nuydens, R.; Dhondt, J.; Poesen, K.; Pintelon, I.; Daniels, A.; Timmermans, J. P.; Meert, T.; Carmeliet, P.; Lambrechts, D., Systemic anti-vascular endothelial growth factor therapies induce a painful sensory neuropathy. *Brain : a journal of neurology* **2012**, *135* (Pt 9), 2629-41.

560

24. Lambert, S.; Bouttier, M.; Vassy, R.; Seigneuret, M.; Petrow-Sadowski, C.; Janvier, S.; Heveker, N.; Ruscetti, F. W.; Perret, G.; Jones, K. S.; Pique, C., HTLV-1 uses HSPG and neuropilin-1 for entry by molecular mimicry of VEGF165. *Blood* **2009**, *113* (21), 5176-85.

565

25. Wang, H. B.; Zhang, H.; Zhang, J. P.; Li, Y.; Zhao, B.; Feng, G. K.; Du, Y.; Xiong, D.; Zhong, Q.; Liu, W. L.; Du, H.; Li, M. Z.; Huang, W. L.; Tsao, S. W.; Hutt-Fletcher, L.; Zeng, Y. X.; Kieff, E.; Zeng, M. S., Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells. *Nat Commun* **2015**, *6*, 6240.

- 570 26. Guo, H. F.; Vander Kooi, C. W., Neuropilin Functions as an Essential Cell Surface
Receptor. *The Journal of biological chemistry* **2015**, 290 (49), 29120-6.
27. Moutal, A.; Martin, L. F.; Boinon, L.; Gomez, K.; Ran, D.; Zhou, Y.; Stratton, H. J.;
Cai, S.; Luo, S.; Gonzalez, K. B.; Perez-Miller, S.; Patwardhan, A.; Ibrahim, M. M.; Khanna,
R., SARS-CoV-2 Spike protein co-opts VEGF-A/Neuropilin-1 receptor signaling to induce
575 analgesia. *bioRxiv* **2020**.
28. Liang, W. C.; Dennis, M. S.; Stawicki, S.; Chanthery, Y.; Pan, Q.; Chen, Y.;
Eigenbrot, C.; Yin, J.; Koch, A. W.; Wu, X.; Ferrara, N.; Bagri, A.; Tessier-Lavigne, M.;
Watts, R. J.; Wu, Y., Function blocking antibodies to neuropilin-1 generated from a designed
human synthetic antibody phage library. *J Mol Biol* **2007**, 366 (3), 815-29.
- 580 29. Pan, Q.; Chanthery, Y.; Liang, W. C.; Stawicki, S.; Mak, J.; Rathore, N.; Tong, R. K.;
Kowalski, J.; Yee, S. F.; Pacheco, G.; Ross, S.; Cheng, Z.; Le Couter, J.; Plowman, G.;
Peale, F.; Koch, A. W.; Wu, Y.; Bagri, A.; Tessier-Lavigne, M.; Watts, R. J., Blocking
neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. *Cancer Cell*
2007, 11 (1), 53-67.
- 585 30. Weekes, C. D.; Beeram, M.; Tolcher, A. W.; Papadopoulos, K. P.; Gore, L.; Hegde,
P.; Xin, Y.; Yu, R.; Shih, L. M.; Xiang, H.; Brachmann, R. K.; Patnaik, A., A phase I study of
the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid
tumors. *Invest New Drugs* **2014**, 32 (4), 653-60.
31. Kim, Y. J.; Bae, J.; Shin, T. H.; Kang, S. H.; Jeong, M.; Han, Y.; Park, J. H.; Kim, S.
590 K.; Kim, Y. S., Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor
tissue penetration and inhibits tumor growth via anti-angiogenesis. *J Control Release* **2015**, 216,
56-68.

32. Kim, Y. J.; Baek, D. S.; Lee, S.; Park, D.; Kang, H. N.; Cho, B. C.; Kim, Y. S., Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in

595 KRAS-mutant non-small cell lung cancer. *Cancer Lett* **2019**, *466*, 23-34.

33. Ko, J. H.; Kwon, H. S.; Kim, B.; Min, G.; Shin, C.; Yang, S. W.; Lee, S. W.; Lee, Y.; Hong, D.; Kim, Y. S., Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076). *Biomolecules* **2020**, *10* (6).

34. Roth, L.; Nasarre, C.; Dirrig-Grosch, S.; Aunis, D.; Cremel, G.; Hubert, P.; Bagnard, 600 D., Transmembrane domain interactions control biological functions of neuropilin-1. *Mol Biol Cell* **2008**, *19* (2), 646-54.

35. Nasarre, C.; Roth, M.; Jacob, L.; Roth, L.; Koncina, E.; Thien, A.; Labourdette, G.; Poulet, P.; Hubert, P.; Cremel, G.; Roussel, G.; Aunis, D.; Bagnard, D., Peptide-based interference of the transmembrane domain of neuropilin-1 inhibits glioma growth in vivo. 605 *Oncogene* **2010**, *29* (16), 2381-92.

36. Arpel, A.; Gamper, C.; Spenle, C.; Fernandez, A.; Jacob, L.; Baumlin, N.; Laquerriere, P.; Orend, G.; Cremel, G.; Bagnard, D., Inhibition of primary breast tumor growth and metastasis using a neuropilin-1 transmembrane domain interfering peptide. *Oncotarget* **2016**, *7* (34), 54723-54732.

610 37. Albrecht, C.; Appert-Collin, A.; Bagnard, D.; Blaise, S.; Romier-Crouzet, B.; Efremov, R. G.; Sartelet, H.; Duca, L.; Maurice, P.; Bennasroune, A., Transmembrane Peptides as Inhibitors of Protein-Protein Interactions: An Efficient Strategy to Target Cancer Cells? *Front Oncol* **2020**, *10*, 519.

38. Binetruy-Tournaire, R.; Demangel, C.; Malavaud, B.; Vassy, R.; Rouyre, S.; Kraemer, 615 M.; Plouet, J.; Derbin, C.; Perret, G.; Mazie, J. C., Identification of a peptide blocking vascular

endothelial growth factor (VEGF)-mediated angiogenesis. *The EMBO journal* **2000**, 19 (7), 1525-33.

39. Jia, H.; Bagherzadeh, A.; Hartzoulakis, B.; Jarvis, A.; Lohr, M.; Shaikh, S.; Aqil, R.; Cheng, L.; Tickner, M.; Esposito, D.; Harris, R.; Driscoll, P. C.; Selwood, D. L.; Zachary, I.

620 C., Characterization of a bicyclic peptide neuropilin-1 (NP-1) antagonist (EG3287) reveals importance of vascular endothelial growth factor exon 8 for NP-1 binding and role of NP-1 in KDR signaling. *J Biol Chem* **2006**, 281 (19), 13493-502.

40. von Wronski, M. A.; Raju, N.; Pillai, R.; Bogdan, N. J.; Marinelli, E. R.; Nanjappan, P.; Ramalingam, K.; Arunachalam, T.; Eaton, S.; Linder, K. E.; Yan, F.; Pochon, S.;

625 Tweedle, M. F.; Nunn, A. D., Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor. *J Biol Chem* **2006**, 281 (9), 5702-10.

41. Starzec, A.; Ladam, P.; Vassy, R.; Badache, S.; Bouchemal, N.; Navaza, A.; du Penhoat, C. H.; Perret, G. Y., Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of
630 the ATWLPPR/neuropilin-1 complex. *Peptides* **2007**, 28 (12), 2397-402.

42. Vander Kooi, C. W.; Jusino, M. A.; Perman, B.; Neau, D. B.; Bellamy, H. D.; Leahy, D. J., Structural basis for ligand and heparin binding to neuropilin B domains. *Proc Natl Acad Sci U S A* **2007**, 104 (15), 6152-7.

43. Getz, J. A.; Cheneval, O.; Craik, D. J.; Daugherty, P. S., Design of a cyclotide

635 antagonist of neuropilin-1 and -2 that potently inhibits endothelial cell migration. *ACS Chem Biol* **2013**, 8 (6), 1147-54.

44. Nissen, J. C.; Selwood, D. L.; Tsirka, S. E., Tuftsin signals through its receptor neuropilin-1 via the transforming growth factor beta pathway. *J Neurochem* **2013**, *127* (3), 394-402.

640 45. Jia, H.; Aqil, R.; Cheng, L.; Chapman, C.; Shaikh, S.; Jarvis, A.; Chan, A. W.; Hartzoulakis, B.; Evans, I. M.; Frolov, A.; Martin, J.; Frankel, P.; Djordevic, S.; Zachary, I. C.; Selwood, D. L., N-terminal modification of VEGF-A C terminus-derived peptides delineates structural features involved in neuropilin-1 binding and functional activity. *ChemBiochem* **2014**, *15* (8), 1161-70.

645 46. Grabowska, K.; Puszko, A. K.; Lipinski, P. F. J.; Laskowska, A. K.; Wilenska, B.; Witkowska, E.; Misicka, A., Design, synthesis and in vitro biological evaluation of a small cyclic peptide as inhibitor of vascular endothelial growth factor binding to neuropilin-1. *Bioorg Med Chem Lett* **2016**, *26* (12), 2843-2846.

47. Richard, M.; Chateau, A.; Jelsch, C.; Didierjean, C.; Manival, X.; Charron, C.; Maigret, B.; Barberi-Heyob, M.; Chapleur, Y.; Boura, C.; Pellegrini-Moise, N., Carbohydrate-based peptidomimetics targeting neuropilin-1: Synthesis, molecular docking study and in vitro biological activities. *Bioorg Med Chem* **2016**, *24* (21), 5315-5325.

48. Fedorczyk, B.; Lipinski, P. F. J.; Tymecka, D.; Puszko, A. K.; Wilenska, B.; Perret, G. Y.; Misicka, A., Conformational latitude - activity relationship of KPPR tetrapeptide analogues toward their ability to inhibit binding of vascular endothelial growth factor 165 to neuropilin-1. *J Pept Sci* **2017**, *23* (6), 445-454.

655 49. Grabowska, K.; Puszko, A. K.; Lipinski, P. F.; Laskowska, A. K.; Wilenska, B.; Witkowska, E.; Perret, G. Y.; Misicka, A., Structure-activity relationship study of a small cyclic

peptide H-c[Lys-Pro-Glu]-Arg-OH: a potent inhibitor of Vascular Endothelial Growth Factor

660 interaction with Neuropilin-1. *Bioorg Med Chem* **2017**, 25 (2), 597-602.

50. Tymecka, D.; Lipinski, P. F. J.; Fedorczyk, B.; Puszko, A.; Wilenska, B.; Perret, G. Y.; Misicka, A., Structure-activity relationship study of tetrapeptide inhibitors of the Vascular Endothelial Growth Factor A binding to Neuropilin-1. *Peptides* **2017**, 94, 25-32.

51. Tymecka, D.; Puszko, A. K.; Lipinski, P. F. J.; Fedorczyk, B.; Wilenska, B.; Sura, K.;
665 Perret, G. Y.; Misicka, A., Branched pentapeptides as potent inhibitors of the vascular endothelial growth factor 165 binding to Neuropilin-1: Design, synthesis and biological activity. *Eur J Med Chem* **2018**, 158, 453-462.

52. Fedorczyk, B.; Lipinski, P. F. J.; Puszko, A. K.; Tymecka, D.; Wilenska, B.; Dudka, W.; Perret, G. Y.; Wieczorek, R.; Misicka, A., Triazolo peptides Inhibiting the Interaction
670 between Neuropilin-1 and Vascular Endothelial Growth Factor-165. *Molecules* **2019**, 24 (9).

53. Puszko, A. K.; Sosnowski, P.; Tymecka, D.; Raynaud, F.; Hermine, O.; Lepelletier, Y.; Misicka, A., Neuropilin-1 peptide-like ligands with proline mimetics, tested using the improved chemiluminescence affinity detection method. *Medchemcomm* **2019**, 10 (2), 332-340.

54. Jarvis, A.; Allerston, C. K.; Jia, H.; Herzog, B.; Garza-Garcia, A.; Winfield, N.;
675 Ellard, K.; Aqil, R.; Lynch, R.; Chapman, C.; Hartzoulakis, B.; Nally, J.; Stewart, M.; Cheng, L.; Menon, M.; Tickner, M.; Djordjevic, S.; Driscoll, P. C.; Zachary, I.; Selwood, D. L., Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. *J Med Chem* **2010**, 53 (5), 2215-26.

55. Novoa, A.; Pellegrini-Moise, N.; Bechet, D.; Barberi-Heyob, M.; Chapleur, Y., Sugar-
680 based peptidomimetics as potential inhibitors of the vascular endothelium growth factor binding to neuropilin-1. *Bioorg Med Chem* **2010**, 18 (9), 3285-98.

56. Borriello, L.; Montes, M.; Lepelletier, Y.; Leforban, B.; Liu, W. Q.; Demange, L.; Delhomme, B.; Pavoni, S.; Jarray, R.; Boucher, J. L.; Dufour, S.; Hermine, O.; Garbay, C.; Hadj-Slimane, R.; Raynaud, F., Structure-based discovery of a small non-peptidic Neuropilins antagonist exerting in vitro and in vivo anti-tumor activity on breast cancer model. *Cancer Lett* **2014**, *349* (2), 120-7.
57. Liu, W. Q.; Megale, V.; Borriello, L.; Leforban, B.; Montes, M.; Goldwaser, E.; Gresh, N.; Piquemal, J. P.; Hadj-Slimane, R.; Hermine, O.; Garbay, C.; Raynaud, F.; Lepelletier, Y.; Demange, L., Synthesis and structure-activity relationship of non-peptidic antagonists of neuropilin-1 receptor. *Bioorg Med Chem Lett* **2014**, *24* (17), 4254-9.
58. Starzec, A.; Miteva, M. A.; Ladam, P.; Villoutreix, B. O.; Perret, G. Y., Discovery of novel inhibitors of vascular endothelial growth factor-A-Neuropilin-1 interaction by structure-based virtual screening. *Bioorg Med Chem* **2014**, *22* (15), 4042-8.
59. Liu, W. Q.; Lepelletier, Y.; Montes, M.; Borriello, L.; Jarray, R.; Grepin, R.; Leforban, B.; Loukaci, A.; Benhida, R.; Hermine, O.; Dufour, S.; Pages, G.; Garbay, C.; Raynaud, F.; Hadj-Slimane, R.; Demange, L., NRPa-308, a new neuropilin-1 antagonist, exerts in vitro anti-angiogenic and anti-proliferative effects and in vivo anti-cancer effects in a mouse xenograft model. *Cancer Lett* **2018**, *414*, 88-98.
60. Mota, F.; Fotinou, C.; Rana, R. R.; Chan, A. W. E.; Yelland, T.; Arooz, M. T.; O'Leary, A. P.; Hutton, J.; Frankel, P.; Zachary, I.; Selwood, D.; Djordjevic, S., Architecture and hydration of the arginine-binding site of neuropilin-1. *The FEBS journal* **2018**, *285* (7), 1290-1304.
61. Powell, J.; Mota, F.; Steadman, D.; Soudy, C.; Miyauchi, J. T.; Crosby, S.; Jarvis, A.; Reisinger, T.; Winfield, N.; Evans, G.; Finnear, A.; Yelland, T.; Chou, Y. T.; Chan, A. W.

- 705 E.; O'Leary, A.; Cheng, L.; Liu, D.; Fotinou, C.; Milagre, C.; Martin, J. F.; Jia, H.; Frankel, P.; Djordjevic, S.; Tsirka, S. E.; Zachary, I. C.; Selwood, D. L., Small Molecule Neuropilin-1 Antagonists Combine Antiangiogenic and Antitumor Activity with Immune Modulation through Reduction of Transforming Growth Factor Beta (TGFbeta) Production in Regulatory T-Cells. *Journal of medicinal chemistry* **2018**, *61* (9), 4135-4154.
- 710 62. Conole, D.; Chou, Y. T.; Patsiarika, A.; Nwabo, V.; Dimitriou, E.; Soudy, C.; Mota, F.; Djordjevic, S.; Selwood, D. L., Discovery of a novel fluorescent chemical probe suitable for evaluation of neuropilin-1 binding of small molecules. *Drug Dev Res* **2020**, *81* (4), 491-500.
63. Sorokina, M.; Steinbeck, C., Review on natural products databases: where to find data in 2020. *Journal of Cheminformatics* **2020**, *12* (1).
- 715 64. Sterling, T.; Irwin, J. J., ZINC 15--Ligand Discovery for Everyone. *J Chem Inf Model* **2015**, *55* (11), 2324-37.
65. Lipinski, C. A., Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discov Today Technol* **2004**, *1* (4), 337-41.
66. Shultz, M. D., Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs. *J Med Chem* **2019**, *62* (4), 1701-1714.
- 720 67. Gupta, M.; Lee, H. J.; Barden, C. J.; Weaver, D. F., The Blood-Brain Barrier (BBB) Score. *Journal of medicinal chemistry* **2019**, *62* (21), 9824-9836.
68. Case, J. B.; Rothlauf, P. W.; Chen, R. E.; Liu, Z.; Zhao, H.; Kim, A. S.; Bloyet, L. M.; Zeng, Q.; Tahan, S.; Droit, L.; Ilagan, M. X. G.; Tartell, M. A.; Amarasinghe, G.; Henderson, J. P.; Miersch, S.; Ustav, M.; Sidhu, S.; Virgin, H. W.; Wang, D.; Ding, S.; Corti, D.; Theel, E. S.; Fremont, D. H.; Diamond, M. S.; Whelan, S. P. J., Neutralizing

Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2. *Cell Host Microbe* **2020**, 28 (3), 475-485 e5.

69. Testa, S.; Paoletti, O.; Giorgi-Pierfranceschi, M.; Pan, A., Switch from oral

730 anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients. *Intern Emerg Med* **2020**, 1-3.

70. Cagno, V.; Tseligka, E. D.; Jones, S. T.; Tapparel, C., Heparan Sulfate Proteoglycans and Viral Attachment: True Receptors or Adaptation Bias? *Viruses* **2019**, 11 (7), 596.

71. Mycroft-West, C. J.; Su, D.; Pagani, I.; Rudd, T. R.; Elli, S.; Guimond, S. E.; Miller, G.; Meneghetti, M. C. Z.; Nader, H. B.; Li, Y.; Nunes, Q. M.; Procter, P.; Mancini, N.; Clementi, M.; Bisio, A.; Forsyth, N. R.; Turnbull, J. E.; Guerrini, M.; Fernig, D. G.; Vicenzi, E.; Yates, E. A.; Lima, M. A.; Skidmore, M. A., Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin. *bioRxiv* **2020**, 2020.04.28.066761.

740 72. Uniewicz, K. A.; Ori, A.; Ahmed, Y. A.; Yates, E. A.; Fernig, D. G., Characterisation of the interaction of neuropilin-1 with heparin and a heparan sulfate mimetic library of heparin-derived sugars. *PeerJ* **2014**, 2, e461.

73. Mamluk, R.; Gechtman, Z.; Kutcher, M. E.; Gasiunas, N.; Gallagher, J.; Klagsbrun, M., Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. *J Biol Chem* **2002**, 277 (27), 24818-25.

745 74. Sastry, G. M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W., Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. *J Comput Aided Mol Des* **2013**, 27 (3), 221-34.

75. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D.

750 T.; Repasky, M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S., Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. *Journal of medicinal chemistry* **2004**, 47 (7), 1739-49.

76. *RDKit: Open-source cheminformatics*, 2018.09.03.

77. *ChemAxon*.

755 78. Janssen, B. J.; Malinauskas, T.; Weir, G. A.; Cader, M. Z.; Siebold, C.; Jones, E. Y., Neuropilins lock secreted semaphorins onto plexins in a ternary signaling complex. *Nat Struct Mol Biol* **2012**, 19 (12), 1293-9.

Table captions

760 **Table 1. Hit and reference compounds with annotations of series assignment, binding Mode, origin, and calculated or experimental data.** Compound ranking (Glide Gscore (kcal/mol)) and calculated properties of the top twenty hits with added reference compounds (A-F). Set: screening library;Source_Idx: reference to internal ID in the screening set; Series: chemotype assignment to hit series 1-9 and known compound series 10-14; Bnd Mode: binding

765 Mode I or II (° denotes constrained docking); BBB score: score for compound probability of having CNS exposure; LogS(7.4) predicted solubility (M) at pH 7.4; Mw molecular weight (Da); cLogP predicted lipophilicity coefficient in octanol/water; HBD number of hydrogen-bond donors; HBA number of hydrogen bond acceptors; Lipinski - a binary (Y/N) assignment of complying with Lipinski rule-of-5; NHOH number of polar NH and OH hydrogens; RotB

770 number of rotatable bonds; TPSA total polar surface area (Å²); na denotes not applicable; n.d. indicates value not determined. All properties were calculated using RDKit. Relative %

inhibition (ELISA VEGF-NRP-1 assay – see Methods section) with standard error of the mean (n=11).

775 Figure Captions

Figure 1. Schematics of NRP-1 domains, VEGF-A₁₆₅ binding, and CendR interaction

network. **A.** Domain architecture of NRP-1 with domain a1 from mouse (PDB ID 4gz9)⁷⁸, domains a2, b1, b2 (PDB ID 2qqm)⁹ and MAM (PDB ID 5L73)¹⁰ from human. Bound Ca²⁺ shown as green spheres, missing loops as dashes, transmembrane domain as a rectangle. GAG indicates region of glycosaminoglycan modification. *Indicates VEGF-A interaction pocket. **B.** Structure of NRP-1 b1 domain, shown as white surface, in complex with the heparin binding domain (exon 7/8) of VEGF-A₁₆₄, shown as cartoon with exon 7 in dark blue, exon 8 in green (PDB ID 4deq)¹⁴. **C.** Details of VEGF-A Glu154 and KPRR₁₆₄ interactions with NRP-1 (close up of view B). Dashes indicate polar or salt-bridge contacts within 3.0 Å.

785

Figure 2. Chemical structures of the top 20 hits. Compounds are grouped by common core motif, shown in magenta. Molecules that adopt binding Mode II (**9, 9a, 14, 17, 18, 16, 19, 20**) have the atoms that form potential hydrogen bonds with Asp320, E319, or G318 colored in blue. The common 2(1H)-pyridone core is highlighted with a gray box in structure **15**.

790

Figure 3. NRP-1 hydrophobic box. The hydrophobic groove formed by residues Tyr297, Tyr253, Trp301, and Thr316 are shown as gray spheres. Compound **1** is shown as green sticks and contacts with hydrophobic box residues within 5 Å shown as dashes. Remaining binding site residues colored red if acidic, yellow if polar, and gray if hydrophobic.

795

Figure 4. Hit compound poses in the NRP-1 b1-domain pocket. **A.** Overlay of hits that adopt binding Mode I. **B.** Overlay of hits that adopt binding Mode II. Polar interactions for representative compounds are shown as dashes for Mode I in **C.** (compound **1**) and **D.** (compound **4**) and for Mode II in **E.** (compound **20**) and **F.** (compound **9**).

800

Figure 5. Structures of selected NRP-1 targeting compounds. Compound A (EG00229) from Ref⁵⁴, compound B (EG01377) from Ref⁶¹, compound C is “compound 1” from Ref⁵⁶, compound D is “bis-guanidinylated compound 32” from Ref⁵⁵, compound E is ChemBridge ID: 7739526 from Ref⁵⁸, and compound F is “NRPa-308” from Ref⁵⁹.

805

Figure 6. Screening of NRP-1/VEGF-A165 inhibitors by in cell western. (A) schematic of VEGF-A triggered phosphorylation of VEGF-R2. Screening of NRP-1/VEGF-A165 inhibitors by in-cell Western. Cathelamine A differentiated (CAD) cells were grown in 96 well plates. Cells were treated with the NRP-1/VEGF-A165 inhibitors at 12.5 μ M or SARS-CoV-2 Spike (100 nM) in combination with 1nM VEGF-A165 as indicated. Cells were stained for pY1175 VEGFR2 as a marker of the activation of the pathway by VEGF-A165. (B) representative micrographs showing the lack of signal in controls with omission of the secondary antibody. Phosphorylated VEGFR2 was increased by the addition of 1 nM VEGF-A165 on the cells. (C) Bar graph showing the levels of pY1175 VEGFR2 normalized to the quantity of cells in each well. # p<0.05 compared to 0.1% DMSO (vehicle) treated cells without VEGF-A165. * p<0.05 compared to 0.1% DMSO + 1 nM VEGF-A165 treated cells, Kruskal-Wallis test with Dunn’s

810

815

multiple test correction (n=7 replicates per condition). Data was analyzed by a repeated measures one-way analysis of variance (post hoc: Dunnett's), *p<0.05.

Figure 7. Screening for VSV-eGFP-SARS-CoV-2 inhibition. Compounds were screened at 25 μ M for inhibition of VSV-eGFP-SARS-CoV-2 infection of Vero-E6-TMPRSS2 cells.

Recombinant Spike S1 domain was included at 68 nM. Cells were infected for 36h prior to live cell automated microscopy and quantification of sum GFP fluorescence intensity, normalized to cell count by HCS CellMask Blue, was measured and for each well and plotted with Prism 6.

Results are presented as mean intensity $\pm$ SEM, # P < 0.05 vs. mock; *P < 0.05 versus DMSO (n=3 replicates). Data was analyzed by a one-way analysis of variance (post hoc: Dunnett's), *p<0.05.

Figure 8. Schematics of pharmacophore models. Thin lines indicate bond distances between pharmacophores while the color indicates the mode of binding (Mode I in red, Mode II in magenta). Pharmacophore features are shown in color (acceptors in green, donors in magenta, and aromatic rings as orange mesh). The neighboring or contact protein residues are listed.

Supplementary Table 1. Physico-chemical properties and structures of top 100 hits, arranged by docking score.

Cmpd	Glide Gscore	Set	Source Idx	Series	Bnd Mode	BBB score	logS (7.4)	Mw	cLogP	HBD	HBA	Lipinski	NHOH	RotB	TPSA	Rel % inhibition
1	-12.1	DIV	29267	1	I	4.2	-5.2	293.33	3.2	2	4	Y	2	4	67	56 ± 7
2	-11.5	DIV	2147	2	I	4.1	-3.3	279.34	0.7	2	4	Y	2	5	84	59 ± 11
3	-10.8	DIV	37503	2	I	3.9	-4.2	342.4	0.7	1	6	Y	1	4	95	n.d.
4	-10.4	DIV	41088	1	I	2.7	-5.0	364.41	2.1	2	7	Y	2	4	96	68 ± 5
5	-10.3	DIV	45423	1	I	2.7	-5.2	378.44	2.9	2	7	Y	2	5	96	42 ± 10
6	-10.3	DIV	42130	2	I	4.3	-2.5	329.4	1.5	1	5	Y	1	6	92	n.d.
7	-9.8	DIV	8757	3	I	3.2	-1.7	218.22	0.9	2	5	Y	2	3	80	18 ± 19
8	-9.7	DIV	8892	3	I	3.0	-1.5	204.19	0.6	3	5	Y	3	2	91	24 ± 16
9	-9.2	DIV	9167	4	II	3.4	-2.3	250.26	0.0	2	5	Y	2	4	95	43 ± 8
10	-11.3	NC1	15860	6	I	1.9	0.0	209.17	-0.9	4	5	Y	4	3	124	n.d.
11	-11.0	NC1	34346	1	I	3.4	0.6	231.21	0.5	2	4	Y	2	3	96	43 ± 16
12	-10.9	NC1	21399	5	I	3.7	-2.3	347.37	-0.9	2	5	Y	2	4	99	n.d.
13	-10.7	NC1	36469	9	I	na	na	358.35	2.4	5	6	Y	5	7	135	n.d.
14	-9.8	NC2	13787	7	II	na	na	312.27	-0.1	5	7	Y	5	6	145	n.d.
15	-9.6	NC2	7454	5	I	4.6	0.6	222.29	0.4	2	3	Y	2	2	56	n.d.
16	-9.6	NC1	16482	9	II	na	na	453.46	0.2	5	5	Y	6	8	171	n.d.
17	-9.4	NC2	13777	7	II ^c	na	na	312.23	-0.4	5	7	Y	5	6	162	12 ± 16
18	-9.1	NC2	13788	7	II ^c	na	na	312.27	-0.1	5	7	Y	5	6	145	n.d.
19	-8.6	NC2	15222	8	II ^c	na	na	396.44	0.6	4	5	Y	6	13	176	n.d.
20	-8.4	NC2	15223	8	II	na	na	396.44	0.6	4	5	Y	6	13	176	n.d.
SARS-CoV2 S1*																54 ± 11
A	-6.4	Ref 54	EG00229	10	II ^c	na	na	497.58	0.8	5	9	Y	7	10	203	33 ± 10
B	-5.8	Ref 61	EG01377	10	II	na	na	586.7	1.8	6	8	N	9	12	212	n.d.
C	-5.2	Ref 56	1	11	II ^c	3.2	-7.9	444.52	4.4	3	5	Y	3	3	88	n.d.
D	-4.3	Ref 55	32	12	II	na	na	500.6	0.0	6	6	Y	9	10	190	n.d.
E	-4.1	Ref 58	CB-7739526	13	na	5.0	-3.5	390.69	4.3	2	4	Y	2	8	51	n.d.
F	-3.5	Ref 59	NRPa-308	14	II	4.1	-6.2	424.52	4.8	2	4	Y	2	7	85	n.d.

Series 1

4

5

Series 3

8

Series 2

2

3

6

Series 4

9a

Series 5

15

Series 6

Series 7

17

18

Series 9

16

Series 8

Series 10

Series 11

Series 12

Series 13

Series 14

A **B**

pY1175 VEGFR2 signal in CAD cells

no secondary antibody

C

A **B**

Mode I

Mode II